Stocks
Reunion Neuroscience Inc.REUN
NASDAQHealthcareBiotechnology$1.12-0.89%
Focused on developing novel psychedelic-derived therapeutics for mental health conditions, this clinical-stage biopharma company is advancing RE104, a proprietary psilocybin-like compound. Investors monitor its progress given the growing interest in alternative psychiatric treatments and potential FDA pathways for psychedelic medicines.
Market Cap: $13.1M52W Range: $0.63 – $21.56
Congressional Interest in Reunion Neuroscience Inc. (REUN)
No congressional trades have been disclosed for Reunion Neuroscience Inc. (REUN) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading REUN?
No congressional trades found for this stock.